Because self-assembled peptide hydrogel has been used to deliver the somatostatin receptor agonist, lanreotide Autogel, as a monthly injection to treat acromegaly and neuroendocrine tumors (NETs) (Pouget et al., 2010; Salvatori et al., 2010; Oberg and Lamberts, 2016; Fattah and Brayden, 2017), these gel-forming antagonists may represent promising candidates for sustained inhibition of CGRP- and/or ADM-mediated migraine pain in patients who have not been sufficiently served by existing migraine drugs. This evidence concerns the gene ADM and migraine disorder.